Analysis software Dr. Noon CKD

disease risk managementmedicalfor nephrology

Retina-based AI solution that predicts the future risk of chronic kidney disease risk. Product Details: - Regulation Info: - Dr. Noon CKD_Korea MFDS: [Product Name] DrNoon CKD / Approved for clinical trial protocol (Jan. 2024) and designated as a Breakthrough Device (Aug. 2023) by the Ministry of Food and Drug Safety of Korea *Dr. Noon CKD is under the approval process by MFDS of Korea AI-powered Solution for Chronic Kidney Disease Risk Assessment Dr. Noon CKD is a retina-based AI solution that predicts the future risk of developing chronic kidney disease. Dr. Noon CKD analyzes the blood vessels in the retina with a simple retinal scan without the need for blood or urine tests and shows the risk of developing chronic kidney disease. How Dr. Noon CKD works: - STEP 1: Eye Scan Take one picture of each eye to capture the retina. - STEP 2: Image Upload The retinal images are uploaded to the healthcare institution’s server or cloud platform. - STEP 3: AI Analysis Artificial intelligence automatically analyzes the images to assess the patient’s risk of chronic kidney disease. - STEP 4: Result Review The risk of chronic kidney disease is determined through an automatically generated report. Comparison with Traditional Methods A comparison with traditional methods highlights Dr. Noon CKD's superior performance over conventional tests in assessing cardiovascular risk. - Blood Test (eGFR) - Urine Test (ACR) Key Benefits - High Accuracy: Provides higher predictive accuracy for chronic kidney disease risk than estimated GFR (eGFR), the current standard kidney function test. - Safe & Non-Invasive: Requires no needle injection or radiation exposure, making it comfortable for patients. - Fast Test Results: Results are delivered promptly, allowing patients to receive their reports without delay. - High Accessibility: It is designed for use in diverse medical settings such as clinics, hospitals, and screening centers, just like standard blood tests. Publications & Webinars - Non-invasive chronic kidney disease risk stratification tool derived from retina-based deep learning and clinical factors - Prediction of systemic biomarkers from retinal photographs: development and validation of deep-learning algorithms - Retinal Photograph-based Deep Learning Predicts CKD among people with preserved kidney function Technical Specifications / Features - AI software medical device - Predicts future risk of chronic kidney disease using retinal images - Non-invasive, no blood or urine test required - Designed for clinical workflow integration - Requires only a fundus camera - Regulatory status: Approved for clinical trial protocol (Korea, Jan. 2024), Breakthrough Device designation (Korea, Aug. 2023)